Mr. Abdoo is Associate Commissioner for Global Policy and Strategy, providing executive oversight, strategic leadership and policy direction to global policy, operations, trade, and diplomacy activities. He joined FDA in 2013 as the inaugural director of the Office of Public Health and Trade. In 2015 he became Associate Commissioner for Regulatory Policy and in 2017 became Deputy Commissioner for Global Regulatory Operations and Policy (acting).

Zainab is a pharmacist with an MSc in Medicine (Pharmaceutical Affairs) from the University of the Witwatersrand and over 15 years of regulatory affairs experience. She is currently Associate Director, Global Regulatory Affairs Policy at Novartis, supporting regulatory policy across the Middle East and Africa. She co-chairs the IFPMA Africa Regulatory Network and is a member of the EFPIA Middle East Regulatory Network. Zainab has led key initiatives in regulatory harmonisation, clinical trial oversight, capability building, and digital transformation, and actively supports the Africa Medicines Agency Treaty Alliance.

Dr. Mimi Darko graduated as a pharmacist with an MBA. Her career in food and health products regulation spans over 30 years. Prior to her appointment as AMA's first DG, she rose through the ranks of the FDA to become its first female CEO in 2017. She led FDA’s designation as a Regional Center of Regulatory Excellence in Medicines Safety, Clinical Trials and Drug Registration. She contributed to the growth of research and of the local manufacturing industries in Ghana Mimi Chairs the Steering Committee of WHO African Vaccines Regulatory Forum and serves on several international and local expert committees. She has received several awards for her exemplary work. She is a devout Christian and married with two children.

Ms. Asmaa Fouad Ismail is currently General Manager of the Biological Products General Administration, the Central Administration of Biological and Innovative Products and Clinical Trials at EDA managing marketing authorization, lot release and laboratory evaluation, and analysis of biological products. Ms. Fouad is also delegate of EDA in ICH & IPRP since December,2021. She is also a member of the Emergency Committee at EDA and has participated in the formulation of many national guidelines in Egypt. She worked in the COVID-19 Vaccines Global Review team with the WHO. She has 20 years of biological products regulatory experience.

Martin Harvey is Head of International Affairs at the European Medicines Agency (EMA), EU. He first joined the EMA legal team after serving as a European affairs consultant in Brussels. He headed the Office of the Executive Director, served as Head of Communication, and then moved to the Agency's International Affairs team. He took an 18-month career break with Unitaid, the WHO-hosted partnership dedicated to innovation in global health from 2019-2020. Martin has served on the DIA Advisory Council for EMEA; and as program advisor for DIA's EuroMeeting and Global Annual Meeting. He holds law degrees from the University of Dundee (UK) and the Vrije Universiteit Brussels (Belgium). He is a Fellow of DIA since 2018.

Sarah Ibrahim is the Associate Director for Stakeholder and Global Engagement in the OGD/ CDER at the U.S. Food and Drug Administration (FDA). Dr. Ibrahim develops OGD strategies to address identified and emerging regulatory challenges in relation to the international nature of the generic drug industry. She established OGD’s current global affairs program, the generic drug cluster which is the first generic drug forum that involves the word leading regulatory agencies. In collaboration with other CDER and FDA offices, she supports stakeholder engagement concerning issues related to globalization of the generic pharmaceutical supply and harmonization of regulatory approaches for generic drugs.

Kwaku Marfo currently holds a role of Market Development Specialist for sub-Sahara Africa with IQVIA. Kwaku is a dynamic Life Sciences leader with 18 years of experience in Pharma and Global Health across US, Europe and Africa markets in diverse therapeutic areas such as Hematology, Rare Disease, Dermatology, Immunology & Rheumatology. Prior to IQVIA, Kwaku spent 11 years at Novartis Pharmaceutical Corporation in both their US and Global Headquarters in New Jersey and Switzerland, respectively. Kwaku recently completed Harvard Medical Executive Program for Senior Life Science Leaders. His educational background includes a Doctor of Pharmacy (PharmD.), Master of Business Administration (MBA), and master's in public health (MPH).

Dr. David Mukanga is Deputy Director Africa Regulatory Systems at the Bill & Melinda Gates Foundation, where he leads the foundation’s Africa regulatory systems optimization portfolio, and the linkage between regulatory systems and health care services. In this role, David supports the development of harmonized, transparent, and predictable regulatory systems covering the lifecycle of medical products in Africa across the national, regional, and continental levels of the ecosystem. His work also involves support for regulatory emergency preparedness. In this role he works side by side with partners on the African continent to facilitate development of new medical products, as well as patient access to quality essential medicines.

Amira is Global Regulatory Policy Director for Europe, Middle East, and Africa at MSD, with over 14 years’ experience in regulatory science and policy. A recognized thought leader in regulatory reliance, work sharing, and harmonization, she builds cross-sector networks to strengthen regulatory practices across the region. She chairs the EFPIA Middle East Regulatory Network and is active in trade associations and forums including the EMA Reliance focus group, EFPIA, IFPMA (notably IFPMA Reliance network and IFPMA Africa Regulatory Network ), and PhRMA. A frequent conference speaker and session leader with multiple publications, she holds a bachelor’s degree in pharmacy and biotechnology from the German University in Cairo.

Tamei Elliott, MS, is the Director of Global Scientific Content at the Drug Information Association (DIA). She leads DIA’s global scientific content strategy, ensuring alignment with regulatory priorities, industry trends, and evolving stakeholder needs across regions. She also established and leads DIA’s Global Science Content Center of Excellence, driving harmonization of content development and strategy across Europe, Asia, North Africa, and the Middle East. With expertise in regulatory science, she brings stakeholders together to address the life sciences industry’s most pressing challenges, driving outcomes that move toward solutions.